C. et al. (2006). Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metabolism and Disposition 34 (1): 75–83. https://doi.org/10.1124/dmd.105.006759.2 Atkinson, A., Kenny, J.R., and Grime, K. (2005). Automated assessment of time‐dependent inhibition of human cytochrome P450 enzymes using liquid chromatography‐tandem mass spectrometry analysis. Drug Metabolism and Disposition 33 (11): 1637–1647. https://doi.org/10.1124/dmd.105.005579.
3 Ayrton, A. and Morgan, P. (2001). Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31 (8–9): 469–497. https://doi.org/10.1080/00498250110060969.
4 Backman, J.T. et al. (2005). Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clinical Pharmacology and Therapeutics 78 (2): 154–167. https://doi.org/10.1016/j.clpt.2005.04.007.
5 Bendayan, R. et al. (1990). Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans. European Journal of Clinical Pharmacology 38 (2): 165–169. https://doi.org/10.1007/BF00265978.
6 Chu, V. et al. (2009). In vitro and in vivo induction of cytochrome P450: A survey of the current practices and recommendations: A Pharmaceutical Research and Manufacturers of America perspective. Drug Metabolism and Disposition 37 (7): 1339–1354. https://doi.org/10.1124/dmd.109.027029.
7 Dunne, J. et al. (2011) ‘Extrapolation of adult data and other data in pediatric drug‐development programs’, Pediatrics, 128(5), p. e1242. doi: 10.1542/peds.2010‐3487.
8 El‐Sankary, W. et al. (2001). Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metabolism and Disposition 29 (11): 1499–1504.
9 EMA (2013). Guideline on the investigation of drug interactions. In: London. https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐investigation‐drug‐interactions‐revision‐1_en.pdf.
10 Fahmi, O.A. and Ripp, S.L. (2010). Evaluation of models for predicting drugdrug interactions due to induction. Expert Opinion on Drug Metabolism and Toxicology 6 (11): 1399–1416. https://doi.org/10.1517/17425255.2010.516251.
11 Franklin, M.R. (1991). Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods in Enzymology 206 (C): 559–573. https://doi.org/10.1016/0076‐6879(91)06126‐N.
12 Galetin, A. et al. (2006). Prediction of time‐dependent CYP3A4 drug‐drug interactions: Impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metabolism and Disposition 34 (1): 166–175. https://doi.org/10.1124/dmd.105.006874.
13 Grime, K.H. et al. (2009). Mechanism‐based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug‐drug interaction prediction methods. European Journal of Pharmaceutical Sciences 36 (2–3): 175–191. https://doi.org/10.1016/j.ejps.2008.10.002.
14 Grimm, S.W. et al. (2009). The conduct of in vitro studies to address time‐dependent inhibition of drug‐metabolizing enzymes: A perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metabolism and Disposition 37 (7): 1355–1370. https://doi.org/10.1124/dmd.109.026716.
15 Harper, T.W. and Brassil, P.J. (2008). Reaction phenotyping: Current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS Journal 10 (1): 200–207. https://doi.org/10.1208/s12248‐008‐9019‐6.
16 Ho, R.H. and Kim, R.B. (2005). Transporters and drug therapy: Implications for drug disposition and disease. Clinical Pharmacology and Therapeutics 78 (3): 260–277. https://doi.org/10.1016/j.clpt.2005.05.011.
17 Hollenberg, P.F., Kent, U.M., and Bumpus, N.N. (2008). Mechanism‐based inactivation of human cytochromes P450s: Experimental characterization, reactive intermediates, and clinical implications. Chemical Research in Toxicology: 189–205. https://doi.org/10.1021/tx7002504.
18 Inotsume, N. et al. (1990). The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. Journal of Clinical Pharmacology 30 (1): 50–56. https://doi.org/10.1002/j.1552‐4604.1990.tb03438.x.
19 Ivanyuk, A. et al. (2017). Renal drug transporters and drug interactions. Clinical Pharmacokinetics: 825–892. https://doi.org/10.1007/s40262‐017‐0506‐8.
20 Jing, X. et al. (2020) ‘Update on therapeutic protein–drug interaction: Information in labeling’, Clinical Pharmacokinetics. 59(1), pp. 25–36. doi: 10.1007/s40262‐019‐00810‐z.
21 Jones, N.S. et al. (2020). Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI. Clinical Pharmacology and Therapeutics 107 (1): 269–277. https://doi.org/10.1002/cpt.1599.
22 Kalgutkar, A.S., Obach, R.S., and Maurer, T.S. (2007). Mechanism‐based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure‐activity relationships and relationship to clinical drug‐drug interactions and idiosyncratic adverse drug reactions. Current Drug Metabolism 8 (5): 407–447. https://doi.org/10.2174/138920007780866807.
23 Kanebratt, K.P. and Andersson, T.B. (2008). HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metabolism and Disposition 36 (1): 137–145. https://doi.org/10.1124/dmd.107.017418.
24 Kato, M. et al. (2005). The quantitative prediction of in vivo enzyme‐induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metabolism and Pharmacokinetics 20 (4): 236–243. https://doi.org/10.2133/dmpk.20.236.
25 Kenny, J. R., Ramsden D., Buckley, D. B. et al. (2018). Considerations from the Innovation and Quality Induction Working Group in Response to Drug‐Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance. Drug Metabolism and Disposition. 46 (9): 1285–1303. https://doi.org/10.1124/dmd.118.081927.
26 Kirch, W. et al. (1987). Pharmacokinetics of bisoprolol during repeated oral administration
